Alkem laboratories has announced significant changes in its senior management structure, filing mandatory disclosures with stock exchanges under regulatory compliance requirements. The pharmaceutical company reported two key personnel transitions affecting its leadership team.

Senior Management Transitions

The company disclosed two distinct changes in its senior management positions through official communication dated March 31, 2026. These changes were reported pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance Details

The disclosures were made in accordance with SEBI Master Circular bearing reference number HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company filed the required information under Schedule III, Part A of the SEBI LODR Regulations.

Key aspects of the regulatory filing include:

• Superannuation Process: Mr. Ravinder Chaklam's departure from senior management was due to superannuation
• Subsidiary Transfer: Mr. Mukesh Tiwari's appointment to the wholly owned subsidiary resulted in cessation from parent company senior management
• Compliance Timeline: The company acknowledged unintentional delay due to inadvertent oversight

Corporate Communication

The disclosure was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, and communicated to both BSE Limited and National Stock Exchange of India Limited. The information has been made available on the company's official website at www.alkemlabs.com .

The company maintains its registered office at ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai, and continues its operations under CIN: L00305MH1973PLC174201. These management changes represent routine corporate governance activities as part of the company's ongoing organizational structure management.

Alkem Laboratories has officially incorporated a wholly owned subsidiary named 'Alkem Pharmaceuticals Scientific Office FZ LLC' in Dubai Healthcare City, UAE, with a total investment of AED 3.67 million. The pharmaceutical company disclosed this strategic development through a regulatory filing under SEBI LODR Regulations, marking a significant milestone in its international expansion strategy.

Subsidiary Structure and Investment Details

The newly incorporated subsidiary has been established with comprehensive financial backing from its parent company. The investment structure demonstrates Alkem's commitment to establishing a strong presence in the Middle East pharmaceutical market.

Business Objectives and Operations

According to the regulatory disclosure, Alkem Pharmaceuticals Scientific Office FZ LLC has been incorporated to undertake manufacturing activities and obtain product registrations, excluding trading operations. This focused approach aligns with Alkem Laboratories' core pharmaceutical business and positions the subsidiary as a manufacturing and regulatory hub for the Middle East region.

Strategic Location Advantage

The establishment of operations in Dubai Healthcare City provides Alkem Laboratories with access to one of the Middle East's most prominent healthcare and pharmaceutical hubs. This strategic location serves as a gateway to the broader Middle East and North Africa (MENA) region, offering significant market expansion opportunities for the company's pharmaceutical products.

Regulatory Compliance and Timeline

The subsidiary was officially incorporated on February 4, 2026, and the disclosure was made to stock exchanges on March 30, 2026, in compliance with SEBI regulations. As a related party transaction due to the wholly owned subsidiary structure, this incorporation represents Alkem's systematic approach to international market entry while maintaining full operational control.

This development reinforces Alkem Laboratories' commitment to geographical diversification and establishes a foundation for capturing emerging opportunities in the Middle East pharmaceutical market.